Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719)
:0719
Want to see HK:0719 full AI Analyst Report?
Top Page
Shandong Xinhua Pharmaceutical Company Limited Class H
(0719)
Select Model
Select Model
Rating:59Neutral
Price Target:
HK$6.00
▼(-10.04% Downside)
Action:Reiterated
Date:06/25/26
The score is held back mainly by weaker recent financial performance (TTM revenue and margin compression) and bearish technical positioning (price below key moving averages with negative MACD). A solid balance sheet, positive free cash flow, and a relatively high dividend yield provide some support, but the high P/E limits the valuation score.
Positive Factors
Solid balance sheet with moderate leverage
Moderate leverage (debt/equity ~0.36) and substantial equity (TTM ~5.33B vs assets ~9.04B) provide financial flexibility to fund operations, R&D or capex. This structural cushion supports resilience through multi-quarter revenue pressure and preserves refinancing options.
Negative Factors
Sharp revenue decline and margin compression
A ~33% TTM revenue drop and meaningful gross/net margin erosion reflect weaker pricing, mix or volume that materially reduce operating leverage. Sustained lower revenue and margins will impair reinvestment capacity, ROE and long-term earnings resilience absent structural recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Solid balance sheet with moderate leverage
Moderate leverage (debt/equity ~0.36) and substantial equity (TTM ~5.33B vs assets ~9.04B) provide financial flexibility to fund operations, R&D or capex. This structural cushion supports resilience through multi-quarter revenue pressure and preserves refinancing options.
Read all positive factors
Shandong Xinhua Pharmaceutical Company Limited Class H (0719) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$9.01B
Dividend Yield4.47%
Average Volume (3M)1.49M
Price to Earnings (P/E)37.7
Beta (1Y)0.65
Revenue Growth5.91%
EPS Growth-40.12%
CountryHK
Employees7,240
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.37
Shares Outstanding195,000,000
10 Day Avg. Volume1,000,110
30 Day Avg. Volume1,490,646
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)0.78
Price to Sales (P/S)0.47
P/FCF Ratio9.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.94
Revenue Forecast (FY)HK$9.35B
Shandong Xinhua Pharmaceutical Company Limited Class H Business Overview & Revenue Model
Company Description
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic...
How the Company Makes Money
The company makes money primarily by selling (1) active pharmaceutical ingredients (APIs) and related chemical intermediates and (2) finished dosage formulations (pharmaceutical preparations). Revenue is generated when it supplies APIs in bulk to ...
Shandong Xinhua Pharmaceutical Company Limited Class H Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
71
Positive
Cash Flow
64
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.72B | 8.75B | 8.47B | 8.10B | 7.50B | 6.56B |
| Gross Profit | 1.62B | 1.64B | 2.04B | 2.32B | 2.04B | 1.77B |
| EBITDA | 359.56M | 988.87M | 1.11B | 1.09B | 1.01B | 908.67M |
| Net Income | 261.19M | 289.89M | 470.02M | 496.51M | 411.06M | 348.55M |
Balance Sheet | ||||||
| Total Assets | 9.04B | 9.19B | 9.02B | 8.29B | 8.27B | 7.33B |
| Cash, Cash Equivalents and Short-Term Investments | 1.27B | 1.40B | 1.25B | 918.33M | 1.16B | 744.66M |
| Total Debt | 1.93B | 1.31B | 1.35B | 1.08B | 1.38B | 1.04B |
| Total Liabilities | 3.46B | 3.73B | 3.80B | 3.51B | 3.92B | 3.68B |
| Stockholders Equity | 5.33B | 5.21B | 4.99B | 4.55B | 4.13B | 3.47B |
Cash Flow | ||||||
| Free Cash Flow | 323.49M | 418.13M | 155.19M | -59.85M | 513.48M | 9.89M |
| Operating Cash Flow | 418.12M | 533.73M | 367.61M | 265.28M | 758.24M | 259.12M |
| Investing Cash Flow | -85.61M | -103.50M | -212.21M | -305.11M | -228.90M | -237.69M |
| Financing Cash Flow | -364.83M | -291.13M | 184.78M | -196.11M | -130.66M | -139.73M |
Shandong Xinhua Pharmaceutical Company Limited Class H Technical Analysis
Negative
6.67
Price Trends
6.11
Negative
6.45
Negative
6.79
Negative
Market Momentum
-0.11
Negative
45.99
Neutral
34.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0719, the sentiment is Negative. The current price of 6.67 is above the 20-day moving average (MA) of 5.84, above the 50-day MA of 6.11, and below the 200-day MA of 6.79, indicating a bearish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 45.99 is Neutral, neither overbought nor oversold. The STOCH value of 34.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0719.
Shandong Xinhua Pharmaceutical Company Limited Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | HK$10.28B | 8.67 | 24.26% | 3.93% | 15.28% | 14.76% | |
72 Outperform | HK$27.28B | 13.36 | 13.95% | 4.09% | 1.48% | -1.55% | |
59 Neutral | HK$9.01B | 37.73 | 5.02% | 4.47% | 5.91% | -40.12% | |
58 Neutral | HK$28.21B | 6.25 | 7.98% | 2.95% | 4.66% | 20.76% | |
56 Neutral | HK$37.29B | 11.36 | 7.70% | 7.15% | 7.32% | 12.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$8.02B | 38.48 | 3.51% | 0.87% | 37.90% | ― |
* Healthcare Sector Average
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
5.77
-0.44
-7.03%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
14.54
-1.95
-11.83%
HK:1513
Livzon Pharmaceutical Group
24.00
-3.49
-12.70%
HK:0460
Sihuan Pharmaceutical Holdings Group
0.87
-0.28
-24.41%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.44
-0.59
-11.76%
HK:1681
Consun Pharmaceutical Group Ltd.
12.70
2.06
19.39%
Shandong Xinhua Pharmaceutical Company Limited Class H Corporate Events
Xinhua Pharmaceutical Wins Approval to Begin Clinical Trials for Novel Pain Drug LXH-2103
Jun 22, 2026
Shandong Xinhua Pharmaceutical Company Limited has received regulatory approval from China’s National Medical Products Administration to commence clinical trials for its LXH-2103 injection, a Class 1 innovative prescription drug. The injecti...
Shandong Xinhua Pharmaceutical Wins China Approval for Sevelamer Carbonate Suspension
Jun 1, 2026
Shandong Xinhua Pharmaceutical has obtained a Drug Registration Certificate from China’s National Medical Products Administration for its Sevelamer Carbonate for Suspension, an oral prescription product classified as a Class 3 chemical drug ...
Shandong Xinhua Pharmaceutical Sets AGM to Review 2025 Results and Governance Changes
May 26, 2026
Shandong Xinhua Pharmaceutical Company Limited has convened its annual general meeting for 26 June 2026 in Zibo, Shandong Province, to review its 2025 operational and financial performance. Shareholders will consider the annual report, the Board r...
Xinhua Pharmaceutical’s Phenobarbital Tablets Clear China’s Generic Consistency Evaluation
May 18, 2026
Shandong Xinhua Pharmaceutical has received approval from China’s National Medical Products Administration confirming that its phenobarbital tablets have passed the national evaluation for consistency of quality and efficacy for generic drug...
Shandong Xinhua Pharmaceutical Wins NMPA Approval for New Ambroxol–Clenbuterol Oral Solution
May 11, 2026
Shandong Xinhua Pharmaceutical Company Limited announced that it has obtained a National Medical Products Administration drug registration certificate for its Ambroxol Hydrochloride and Clenbuterol Hydrochloride oral solution, a Class 3 chemical p...
Shandong Xinhua Pharmaceutical Wins NMPA Approval for Benserazide Hydrochloride API
May 8, 2026
Shandong Xinhua Pharmaceutical Company Limited has secured marketing authorisation from China’s National Medical Products Administration for its domestically produced active pharmaceutical ingredient benserazide hydrochloride. The approval c...
Shandong Xinhua Pharma Q1 Profit Drops Despite Stable Revenue and Asset Base
Apr 28, 2026
Shandong Xinhua Pharmaceutical Company Limited reported essentially flat operating income of RMB 2.42 billion for the first quarter of 2026, while net profit attributable to shareholders fell 25.2% year on year to RMB 83.9 million and earnings per...
Xinhua Pharmaceutical Secures Approval to Take Over Potassium Chloride Granules Marketing Rights
Apr 24, 2026
Shandong Xinhua Pharmaceutical has received regulatory approval from China’s National Medical Products Administration for a supplementary drug application related to its Potassium Chloride Granules, specifically approving a change in the pro...
Shandong Xinhua Pharmaceutical Wins NMPA Approval for Bumetanide Injection
Apr 15, 2026
Shandong Xinhua Pharmaceutical has obtained National Medical Products Administration approval for its BUMETANIDE Injection, a prescription diuretic product in 2ml:0.5mg and 4ml:1mg specifications, classed as a Class 3 chemical drug for domestic pr...
Shandong Xinhua Pharma Sets Board Meeting to Review Q1 2026 Results
Apr 15, 2026
Shandong Xinhua Pharmaceutical Company Limited has scheduled a board meeting to be held at its headquarters in Zibo, Shandong, on 28 April 2026. The board will review and consider approval of the unaudited financial results of the company and its ...
Xinhua Pharmaceutical Wins NMPA Approval for New Electrolyte Injection
Apr 7, 2026
Shandong Xinhua Pharmaceutical Company Limited has obtained a Drug Registration Certificate from China’s National Medical Products Administration for its Sodium Potassium Magnesium and Calcium Concentrated Solution for Injection. The approva...
Xinhua Pharmaceutical Wins Approval to Take Over Galculus Bovis and Metronidazole Capsule Rights
Apr 1, 2026
Shandong Xinhua Pharmaceutical has obtained regulatory approval from China’s National Medical Products Administration to change the marketing licence holder for its Galculus Bovis and Metronidazole Capsules. The approval confirms the product...
Shandong Xinhua Pharmaceutical Announces Retirement of Non-Executive Director
Mar 31, 2026
Shandong Xinhua Pharmaceutical Company Limited has announced the resignation of non-executive director Xu Lie, who also served on the board’s Strategic Development Committee, due to retirement by reason of age. His resignation took effect on...
Shandong Xinhua Pharmaceutical Sets Out Board and Committee Structure
Mar 31, 2026
Shandong Xinhua Pharmaceutical Company Limited has disclosed the current composition of its board of directors, which includes executive, non-executive and independent non-executive members, with Mr. He Tongqing serving as chairman. The company ha...
Shandong Xinhua Pharma Moves to Update Articles After Share Capital Increase
Mar 27, 2026
Shandong Xinhua Pharmaceutical Company Limited plans to amend its Articles of Association after its issued share capital increased by 6,906,900 ordinary shares to 696,683,435, following option exercises under its 2021 share option scheme. The boar...
Shandong Xinhua Pharmaceutical Proposes RMB 0.15 Final Dividend for 2025
Mar 27, 2026
Shandong Xinhua Pharmaceutical Company Limited has proposed a final ordinary cash dividend of RMB 0.15 per share for the financial year ended 31 December 2025, subject to shareholder approval. Key details including the shareholders’ approval...
Shandong Xinhua Pharmaceutical Publishes Audited 2025 Annual Results
Mar 27, 2026
Shandong Xinhua Pharmaceutical Company Limited, a PRC-based drug maker listed in both Hong Kong and Shenzhen, has released its audited consolidated results for the financial year ended 31 December 2025, prepared in accordance with China Accounting...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.